This paper presents the results of different laboratory assays of typhoid vaccines and the relation of the estimates to efficacy in four recent field trials which were coordinated by the World Health Organization. Two vaccines, K and L, were used in British Guiana and Yugoslavia. Vaccine K was used in Poland in comparison with four Polish typhoid vaccines, and vaccine L was used in the USSR in comparison with four Russian typhoid vaccines. Our study included vaccines K and L, three of the Polish vaccines, one of the Russian vaccines, and the U.S. reference typhoid vaccine NIH 4. Vaccine K was acetone-killed and dried, and vaccine L was heat-phenol killed and dried. Descriptions of (i) their preparations have been reported by Division of Immunology, Walter Reed Army Institute of Research (4) and (ii) their physical and chemical properties by Walter Reed Army Institute of Research, and International Laboratory for Biological Standards, Statens Seruminstitut (18) . The Polish vaccines were acetone-killed and dried (P), formaldehydekilled and phenol-preserved (N), and a lysate adsorbed on AI(OH)3 (T; 13); the Russian vaccine V was alcohol-treated (8) .
In the field trials, both vaccines K and L afforded significant protection against typhoid, but vaccine K was significantly more effective than vaccine L both in British Guiana (17) and in Yugoslavia (20) . In Poland, vaccines K, P, and N afforded better protection than vaccine T (13) . In Russia, vaccines L and V afforded significant protection (8) but not as high as the acetone vaccines elsewhere. The results of the four trials have been summarized by Cvjetanovic and Uemura (3) .
Twenty-one laboratories participated in the assay of the vaccines K and L. Each participant was requested to perform two assays by specified procedures-H, 0, and Vi antibody response of rabbits and an active mouse protection test-and by one other type of assay of their choice. Spaun and Uemura (15) organized and reported the results, and concluded that none of the potency tests in animals reliably reflected the evidence obtained in human beings, although some of the assays seemed to offer promise of ability to distinguish between the potencies of typhoid vaccines in a manner reflecting their efficacy in man.
One of the outstanding findings shown both by the Moscow assay data (11) and by our data was that the route of vaccination of the mouse significantly affected the measured relative potencies of vaccines K and L. Spaun (14) identified these results in a separate paper. In this report, it is shown that by the use of different assays relative potencies of different types of vaccine reflected the relative degrees of protection of the six vaccines for man. The intraperitoneal (ip) vaccination and mucin challenge assay (type N ip) reflected the relative human efficacy of the acetone, the heat-phenolized, the lysate, and probably the formaldehyde-killed and phenol-treated vaccines. The subcutaneous (sc) vaccination and mucin challenge assay (type N sc) reflected the relative efficacy of the heatphenolized and alcohol-treated vaccines. The differences obtained within and between vaccines by different assays suggest that the mouse differentiated three protective factors.
The relative potency of vaccines K and L (type N ip assay) was not altered by the use of a 14- (4) .
The types of assay are designated as in the report on the international collaborative studies (15) . Their differential features are listed in Table 2 . The majority of our tests were performed by the method specified Heat-phenol USA Reference Typhoid Vaccine * Our estimation was calculated from information that the dry mass corresponding to 50 ml of vaccine of a density of 109 bacteria per milliliter varied from 0.02 to 0.03 g and that the total nitrogen was 0.072 mg/mg of dry mass; the variation in moisture content was not taken into account.
t Prepared with strain V-58; other vaccines were prepared with strain Ty 2. IV; in each test of experiment VI, some of the mice were vaccinated ip and some sc, and all received a common challenge. The route of vaccination significantly affected the ED50 of vaccine K. The ED5o by ip vaccination was only 0.256 of the ED50 by sc vaccination (0.828 X 106 bacteria versus 3.234 X 106 bacteria). On the other hand, vaccines L and NIH 4 tended to afford better protection by sc than by ip vaccination (1.20 and 1.68 greater, respectively).
The influence of route of vaccination was reflected likewise in the relative potencies of the vaccines (Table 4 ). The potency of vaccine K relative to vaccine L by the ip assay was 3.69 (nine tests) and by the sc assay 0.78 (nine tests). Each value was significantly different from unity. Table 5 shows the results obtained when the challenge was suspended in saline. The difference between the ED5o values of vaccine K by sc and ip vaccination (experiment VII) was greater than with the mucin challenge (6.4-and 3.9-fold, respectively). The relative potency of 0.54 for vaccine K was also lower. With vaccine L, ip vaccination, only one of the four tests showed a graded-dose response. In this test the ED50 of vaccine K was significantly less than for vaccine L (20 X 106 bacteria versus 206 X 106 bacteria), and the potency of vaccine K relative to vaccine L was 10; with mucin challenge, it was 3.69.
With the World Health Organization prescribed type B assay (experiment I, Table 5 ) the potency of vaccine K relative to vaccine L was 0.72. The difference between 0.72 and 0.54 obtained in the one-sc assay approached significance at the 95 % confidence level. (Two vaccinations tend to reduce the assayed difference in protective activity between vaccines.) The difference between the one-sc-saline and one-scmucin challenge potencies (0.54 and 0.78), however, was significant.
Although the results with vaccine L, ip vaccination and saline challenge, were not entirely satisfactory, the overall results showed, as did the mucin challenge assays, that the potency of vaccine K relative to vaccine L was reversed by the two routes of vaccination. The difference was more marked with the saline challenge. Table 6 shows that, by different routes of vaccination and different suspending fluids of the challenge culture, vaccine K had an immunological factor different from vaccine L. With type N ip assay, the slope coefficients of the doseresponse regression lines of vaccines K and L differed significantly. A significant difference was observed also in another experiment (11) in which strain T-63 was used for challenge; the slopes for vaccines K and L were 0.85 + 0.14 and 1.40 ± 0.17, respectively. The difference between the slopes suggests that the greater protective activity of vaccine K was not due to a higher concentration of a common factor.
On the other hand, with type B or type P ip * Potency is or is for practical purposes significantly different from unity.
Significantly less than each sc EDw of vaccine K. Potency of USSR vaccine V. Table 8 shows the ED1o of vaccines K, L, and V and the potencies of vaccines K and V relative to vaccine L that were obtained in two types of assay, N ip and N sc. By ip vaccination, vaccine V was three times more potent than vaccine L and similar in VOL. 91, 1966 Influence of other variables in the potency assay. In addition to the study of the influence of the above-reported variables in the mouse protection assay on potency values, the influence of two other factors was studied briefly-time interval between vaccination and challenge, and the challenge strain. The type N ip assay was used. Table 10 shows that an interval of 7 or 14 days did not materially effect the ED50 or the relative Table 11 . The comparison was limited to the participants that received two injections of vaccine and to those age groups or areas in which the particular vaccines were compared. The reported attack rates were adjusted to rates per 100,000 for the period of observation.
In British Guiana and Yugoslavia, vaccine K afforded better protection than vaccine L. The effective ratios of protection were 4.3 and 2.3.
One reason for the lower degree of protection in Yugoslavia has been attributed to a higher infective dose caused by exposure to heavily polluted water for 3 weeks in one study area; the rate of cases per 100,000 was much higher in Yugoslavia than in British Guiana. In the laboratory assay, vaccine K was 3.69 (2.70 to 5.03) more potent than vaccine L. This difference is in good agreement with the difference in degree of protection of the two vaccines for man, especially if the degree of infective doses in man is considered.
In Poland, the protective activity of vaccines K, N, and T was observed in children, and of vaccines P and N in adults. The numbers of cases of typhoid among the children immunized with vaccines K and N were only four and three, and were too small to give a reliable protective ratio. Their ratio of 1.3 was higher than the laboratory relative potency of 0.57. However, when the comparison was made with P vaccine, which in the doses used was equal in potency to vaccine K, the protective ratio of 0.66 (adult population) was comparable to the laboratory value of 0.57 but may not be valid because of the small number of cases. With vaccines K and T, the effective ratio was in agreement with the laboratory relative potency (0.33 and 0.36).
In the USSR trials (12 areas), vaccine V was 1.25 more effective than vaccine L. By the type N ip assay, vaccine V was 3.06 times more potent than vaccine L. However, by the type N sc assay vaccine V was only 1.54 more potent and is not different from the relative protection in man.
DIscussIoN
The antibody responses of rabbits to H, 0, and Vi antigens did not satisfactorily reflect the relative efficacies of vaccines K and L for man. The differences obtained between collaborative laboratories (15) cast doubt on the suitability of the rabbit for measurement of Vi content or even for its detection. Joo', Pusztai, and Juhasz (7) In mouse protection assays, the relative potencies of three types of vaccine (acetone, heatphenol-treated, and alcohol-treated) varied significantly with the type of assay used. The slope coefficients of the dose-response lines, also, showed significant variations. In the sc-vaccination and either mucin-or saline-challenge assay of vaccines K and L, the slope coefficients were similar in a particular assay. It appeared that differences in protective activity were due to a dilution of a common factor. In the ip-vaccination mucin-challenge assays (type N ip) of the same vaccines, the slope coefficients were significantly different, and the significantly higher protective activity of vaccine K by this assay appeared to be due to an additional protective factor. The slope of vaccine L by this assay was not different from its slope by the type N sc assay. The alcoholtreated vaccine appeared to have a third protective factor for the mouse. In the type N ip assay, potency and slope coefficient of vaccine V were the same as those of vaccine K and significantly different from those of vaccine L. However, by the type N sc, vaccine V was significantly more potent than either vaccine K or L, whereas vaccine K was significantly less potent than vaccine L; the slope coefficients of the three vaccines were similar. Type N ip assay reflected the difference in degree of protection of vaccines K and L for man, and type N sc appeared to reflect the relative efficacy of vaccines L and V for man.
It is of interest to note that in the type N sc assay (mucin challenge) vaccine K was slightly but significantly less potent than vaccine L (0.78) and that in type P sc assay (saline challenge) the difference was more marked (0.54); the difference between these ratios was significant. Melikova et al. (11) likewise observed with the use of type P sc assay that vaccine K was less potent than vaccine L. Their value was 0.26. With the type P ip assay, their potency value of vaccine K relative to vaccine L was 3.63, the same as our value of 3.69 obtained with the type N ip assay.
In opposition to the above results, three other laboratories, with the use of the type P sc assay, reported that vaccine K was significantly more potent than vaccine L (15) . Joo et al. (7) reported similar results (their results may have been in the cooperative report). Nevertheless, the relative values were of a lower order than was observed by us and by Melikova et al. (11) . Further, the type B and C assays which employed two sc vaccinations and saline challenge did not differentiate the potency of vaccines K and L for man (15) . It seems definite that ip vaccination of the mouse is better than sc vaccination to differentiate the potencies of acetone and heatphenolized vaccines for man.
The fact that vaccine L was relatively more protective against saline than was mucin challenge suggests that vaccine L exerted a greater antiendotoxic activity than vaccine K. Conversely, vaccine K exerted a greater antibacterial activity against mucin challenge. The challenge doses were approximately 5 X 107 and 1 x 103 bacteria, respectively. Since Landy (9) obtained equal protection with isolated, soluble Vi antigen by ip, sc, and intravenous vaccination, the role of Vi antigen in either vaccine K or L in the different protective responses remains unknown.
The type N ip assay appeared to differentiate the efficacies of the formaldehyde-phenol-preserved (N) and the acetone vaccines (K and P). The number of cases of typhoid, however, was too small to provide a valid effective ratio. The PIITMAN AND BOHNER final report of the Polish field trial may provide adequate data for a firm conclusion. For the lysate vaccine T, the type N ip assay gave excellent correlation with human and laboratory protective activity relative to vaccine K (0.36 and 0.33).
More work is needed to establish that type N sc assay reliably reflects relative potency of alcohol-treated and heat-phenol vaccines. Ikic (6) reported that the two sc-vaccination salinechallenge assay (type C) differentiated an alcohol-treated and a heat-phenol vaccine in the same order as human effectiveness. The problem of differentiating the potency of alcohol-treated and heat-phenol vaccines arose in the assay of the potency of the vaccines used in the earlier Yugoslav field trial (19) . A heat-phenol vaccine conferred more protection than an alcohol-treated vaccine. In mouse potency assays, Edsall et al.
(5), using ip vaccination and either mucin or saline challenge, found the alcohol-treated vaccine to be more potent; Standfast (16), using subcutaneous vaccination and either mucin or sahne challenge found no significant difference between the two vaccines (the heat-phenol vaccine, however, was slightly more potent); Ikic, (6), with use of two sc doses and saline challenge and the application of strict randomization procedures (type C assay), found the heat-phenol vaccine to be significantly more potent than the alcohol-treated vaccine. It now appears on the basis of our present results that the conflicting potency estimates were due to the use of different routes of immunization of the mice.
Landy and his associates (for references, see 10) have shown that Vi antigen is an excellent protective antigen for the mouse against Salmonella typhosa infection. This antigen, isolated from a number of V-form Enterobacteriaceae, has the same immunological specificity. However, the earlier Yugoslav field trial and the four recent trials have not furnished evidence that Vi antibody plays a role in the immunity of man against typhoid. With a difference in response of man and mouse, it is not surprising that difficulty has been encountered in obtaining a direct correlation between mouse potency and efficacy in man.
It is reasonable to assume that a typhoid vaccine containing a high level of Vi antigen will cause a too high potency value, at least in the type N ip assay. Unfortunately, there is no information on the quantity of Vi antigen in the field trial vaccines. Hence, it is not known whether the observed suitability of the type N ip assay for differentiating the acetone and heat-phenol vaccines and the type N sc assay for differentiating alcoholtreated and heat-phenol vaccines is related to the Vi antigen or another factor. A simple direct quantitation assay for measuring Vi antigen would be helpful in assessing the role of Vi antigen.
In our hands, the mucin challenge after ip vaccination gave more reproducible results than did saline challenge. Further, saline challenge accentuated the reversal in relative potency of vaccines K and L after sc vaccination. Edsall et al. (5) reported that the strength of the saline challenge was more difficult to reproduce than the mucin challenge. Experiments are needed to determine whether the difference obtained with mucin and saline challenge is due to the protective activity against small numbers of bacteria in mucin or large numbers in saline, that is, antibacterial or antiendotoxic protection. Whatever challenge menstruum is used, variability from test to test will occur, more so in some laboratories than in others.
A study of the influence of other variable factors is indicated. Objections have been raised to the use of the same route of vaccination and challenge because of purported nonspecific immunity. However, the use of a 14-day interval between vaccination and challenge did alter the relative potency of vaccines K and L obtained with a 7-day interval. Edsall et al. (5) found that 6-and 14-day intervals did not significantly affect results. It is of interest to note that we obtained the same relative potency in sc vaccination and saline challenge assays with 7-and 28-day intervals, and that ip vaccination of vaccine L followed 7 days later with a saline challenge gave irregular protection ( Table 5 ).
The use of another S. typhosa strain, T-63, for challenge in the type N ip assay did not significantly affect relative potency of vaccines K and L. Results from test to test varied more than with Ty 2 challenge, probably due to lower virulence. Laboratory 21 in the collaborative study (15) used T-63 in the type N ip assay with the result that vaccine K was 15.3 more potent than vaccine L.
Besides reducing the variability of the test, investigations are indicated to determine (i) why different types of typhoid vaccine elicit different relative degrees of protective response by intraperitoneal and subcutaneous vaccination, and (ii) the influence of other methods of preparation of the vaccine on potency and its assay.
In spite of the unknown factors, it appears for the time being that the ip-vaccination mucinchallenge assay (type N ip) can be used with a certain degree of assurance in routine potency evaluation of each lot of typhoid vaccine in relation to a reference vaccine, provided the vaccines are not prepared by alcohol precipitation.
One objective in our study was to relate the
